XOMA (XOMA) Competitors $26.67 -0.47 (-1.73%) (As of 02:04 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends XOMA vs. MYGN, INVA, OPK, IRWD, SGMO, EBS, CDXS, RIGL, VNDA, and VSTMShould you be buying XOMA stock or one of its competitors? The main competitors of XOMA include Myriad Genetics (MYGN), Innoviva (INVA), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), Emergent BioSolutions (EBS), Codexis (CDXS), Rigel Pharmaceuticals (RIGL), Vanda Pharmaceuticals (VNDA), and Verastem (VSTM). These companies are all part of the "biotechnology" industry. XOMA vs. Myriad Genetics Innoviva OPKO Health Ironwood Pharmaceuticals Sangamo Therapeutics Emergent BioSolutions Codexis Rigel Pharmaceuticals Vanda Pharmaceuticals Verastem Myriad Genetics (NASDAQ:MYGN) and XOMA (NASDAQ:XOMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, community ranking, dividends, valuation, media sentiment, analyst recommendations and institutional ownership. Is MYGN or XOMA more profitable? Myriad Genetics has a net margin of -14.09% compared to XOMA's net margin of -151.34%. Myriad Genetics' return on equity of -4.51% beat XOMA's return on equity.Company Net Margins Return on Equity Return on Assets Myriad Genetics-14.09% -4.51% -3.07% XOMA -151.34%-24.95%-9.64% Do analysts rate MYGN or XOMA? Myriad Genetics currently has a consensus price target of $24.27, indicating a potential upside of 75.38%. XOMA has a consensus price target of $81.50, indicating a potential upside of 204.67%. Given XOMA's stronger consensus rating and higher probable upside, analysts plainly believe XOMA is more favorable than Myriad Genetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Myriad Genetics 3 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.00XOMA 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer MYGN or XOMA? Myriad Genetics received 32 more outperform votes than XOMA when rated by MarketBeat users. However, 66.21% of users gave XOMA an outperform vote while only 52.99% of users gave Myriad Genetics an outperform vote. CompanyUnderperformOutperformMyriad GeneticsOutperform Votes46952.99% Underperform Votes41647.01% XOMAOutperform Votes43766.21% Underperform Votes22333.79% Do institutionals & insiders have more ownership in MYGN or XOMA? 99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 95.9% of XOMA shares are held by institutional investors. 2.1% of Myriad Genetics shares are held by company insiders. Comparatively, 7.2% of XOMA shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable earnings & valuation, MYGN or XOMA? XOMA has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than XOMA, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMyriad Genetics$823.60M1.53-$263.30M-$1.30-10.65XOMA$4.76M66.20-$40.83M-$3.48-7.69 Does the media refer more to MYGN or XOMA? In the previous week, Myriad Genetics had 6 more articles in the media than XOMA. MarketBeat recorded 10 mentions for Myriad Genetics and 4 mentions for XOMA. XOMA's average media sentiment score of 0.84 beat Myriad Genetics' score of 0.08 indicating that XOMA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral XOMA 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, MYGN or XOMA? Myriad Genetics has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Comparatively, XOMA has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. SummaryMyriad Genetics beats XOMA on 9 of the 17 factors compared between the two stocks. Ad DTI$20k in extra income? My friend Alex Reid just might have created my favorite strategy right now. You see, Alex has figured out how to cut-the-corner so to speak, and be one of the laziest traders possible…. While still showing his traders how to target big money. This past year, his LIVE “lazy trade” alerts have delivered impressive results—and that’s only a fraction of the opportunities he’s shared. And that’s just just a quarter of the total trade alerts he’s sent out. The true total profit potential his beta-testers have had the chance to target is far larger than $20k. Alex recorded a special video training where he reveals exactly how much. Get XOMA News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XOMA vs. The Competition Export to ExcelMetricXOMAPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$315.12M$6.84B$5.13B$9.28BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-7.6910.77135.2417.51Price / Sales66.20283.871,174.53134.92Price / CashN/A56.6540.4837.95Price / Book3.475.384.884.94Net Income-$40.83M$151.62M$118.56M$225.30M7 Day Performance-8.86%-4.82%14.97%-1.11%1 Month Performance-10.86%2.04%15.07%7.29%1 Year Performance68.24%16.11%34.31%23.06% XOMA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XOMAXOMA4.4241 of 5 stars$26.67-1.7%$81.50+205.6%+72.3%$314.25M$9.71M-7.6610MYGNMyriad Genetics4.5662 of 5 stars$14.06-2.6%$24.27+72.6%-33.4%$1.28B$823.60M-11.102,700INVAInnoviva2.1507 of 5 stars$18.54-0.2%N/A+18.6%$1.16B$310.46M26.93112Short Interest ↓OPKOPKO Health4.4515 of 5 stars$1.56-2.2%$2.75+76.8%+4.2%$1.06B$711.41M-8.343,930Positive NewsIRWDIronwood Pharmaceuticals4.1063 of 5 stars$3.52-0.3%$10.40+195.5%-68.3%$563.31M$442.73M-117.67220SGMOSangamo Therapeutics1.9033 of 5 stars$2.52+22.7%$7.00+178.3%+579.4%$524.76M$176.23M-3.11480Analyst UpgradeEBSEmergent BioSolutions4.1689 of 5 stars$8.87+4.6%$14.00+57.8%+268.9%$480.61M$1.09B-2.071,600CDXSCodexis4.2441 of 5 stars$5.67+2.5%$8.33+47.0%+95.5%$461.41M$64.45M-6.36250Positive NewsRIGLRigel Pharmaceuticals4.2964 of 5 stars$19.25+1.8%$36.20+88.1%+43.0%$338.99M$116.88M135.08147VNDAVanda Pharmaceuticals4.3318 of 5 stars$4.66+1.1%$15.50+232.6%+21.9%$271.72M$190.86M-16.54203VSTMVerastem3.6237 of 5 stars$4.74+5.8%$12.50+163.7%-39.6%$210.96M$10M-1.4050News CoveragePositive NewsGap Up Related Companies and Tools Related Companies Myriad Genetics Alternatives Innoviva Alternatives OPKO Health Alternatives Ironwood Pharmaceuticals Alternatives Sangamo Therapeutics Alternatives Emergent BioSolutions Alternatives Codexis Alternatives Rigel Pharmaceuticals Alternatives Vanda Pharmaceuticals Alternatives Verastem Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XOMA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
